New PyMOL interface extends access to Optibrium’s structure-based design method Surflex-Dock
CAMBRIDGE, UK, 04 February 2025 – Optibrium, a leading developer of software and AI solutions for molecular design today announced the introduction of a new PyMOL Graphical User Interface (GUI) for Surflex-Dock, its industry-leading structure-based design method, which is part of the company’s BioPharmics 3D molecular modelling suite. The intuitive and highly visual GUI makes Surflex-Dock more easily accessible to computational and medicinal chemists modelling protein-ligand interactions.
Surflex-Dock is a highly automated molecular docking method that provides top-tier docking enrichment in rigorous independent benchmarks. Its accurate pose prediction has been shown to outperform other docking methods, giving a more realistic picture of the binding of unknown (non-cognate) ligands for both small molecules and large macrocycles1, thereby improving the 3D design of potent ligands.
Initially, Surflex-Dock was developed as a command-line tool, bringing advanced molecular docking to expert users. The GUI has been developed as a no-code plugin for PyMOL, an open-source molecular visualisation tool used extensively by computational and medicinal chemists. The addition of the Surflex-Dock plugin for PyMOL will make Surflex-Dock much more widely accessible to the molecular modelling community. Surflex-Dock’s command-line interface will continue to be supported for expert-level use and large-scale batch processing.
Ann Cleves, VP of Application Science, BioPharmics Division, Optibrium, said: “To truly transform drug discovery, advanced methods need to be accessible by all those in the community who would benefit most. I am delighted to see this next step in our programme of development for the BioPharmics Platform, in which we are making cutting-edge methods for 3D molecular design more accessible to computational and medicinal chemists.”
The Surflex-Dock plugin for PyMOL is available to users with a BioPharmics license at no additional cost.
Related content from across the site
Optibrium secures multi-million-pound financing package from Shawbrook to accelerate business growth
Proceeds will accelerate Optibrium’s product development and expand the global reach of its computational chemistry and AI-driven discovery technology. CAMBRIDGE,…
Optibrium partners with TalTech on EU-funded PhD programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism. CAMBRIDGE, UK, 02 July 2025…
Optibrium Widens Access to Industry-Leading Docking Method
New PyMOL interface extends access to Optibrium’s structure-based design method Surflex-Dock CAMBRIDGE, UK, 04 February 2025 – Optibrium, a leading…
